Association Between Topiramate and Zonisamide Use During Pregnancy and Low Birth Weight

作者：Hernandez Diaz Sonia; Mittendorf Robert; Smith Caitlin R; Hauser W Allen; Yerby Mark; Holmes Lewis B^*

来源：Obstetrics and Gynecology, 2014, 123(1): 21-28.

DOI：10.1097/AOG.0000000000000018

OBJECTIVE: To assess the possible effects of topiramate and zonisamide use during pregnancy on fetal growth. %26lt;br%26gt;METHODS: The study population was the singleton live-borns born to women who enrolled in the North American Antiepileptic Drug Pregnancy Registry between 1997 and 2012. Data were collected through telephone interviews at enrollment, 7 months of gestation, and postpartum. The prevalence of small for gestational age at birth among neonates exposed to topiramate and to zonisamide when either was used as monotherapy during pregnancy was compared with that among neonates exposed to lamotrigine monotherapy, a weight-neutral therapy, and the most common antiepileptic drug in the Registry. Relative risks (RRs) and 95% confidence intervals (CIs) were estimated with multivariable log-binomial regression to control for potential confounders. %26lt;br%26gt;RESULTS: Data were available for 347 topiramate, 98 zonisamide, and 1,581 lamotrigine-exposed neonates. The mean gestational length was 39 weeks for all comparison groups. Prenatal exposure to topiramate or zonisamide was associated with a mean lower birth weight of 221 and 202 g, respectively, and a mean lesser neonatal length of 1 cm as compared with lamotrigine exposure (p %26lt;.01). The prevalence of small for gestational age was 6.8% for lamotrigine, 17.9% for topiramate (RR 2.4, 95% CI 1.8-3.3) and 12.2% for zonisamide (RR 1.6, 0.9-2.8). Similar results were found when a group of 457 unexposed neonates was used as the reference. %26lt;br%26gt;CONCLUSIONS: Topiramate and zonisamide have been shown to reduce weight in adults. Our finding of a decrease in mean birth weight and length among neonates exposed in utero raises concern.

• 出版日期2014-1